ICPT:NSD-Intercept Pharmaceuticals, Inc (USD)

COMMON STOCK | Biotechnology | NSD

Last Closing Price

USD 44.05

Change

-1.32 (-2.91)%

Market Cap

USD 1.45B

Volume

1.10M

Average Target Price

USD 75.43 (+71.25%)
Average Analyst Rating

Verdict

Fundamental Analysis

Verdict

About

Intercept Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of therapeutics to treat progressive non-viral liver diseases in the United States, Europe, and Canada. Its lead products candidate is the Ocaliva, a farnesoid X receptor agonist used for the treatment of primary biliary cholangitis (PBC) in combination with ursodeoxycholic acid in adults. The company is also developing Ocaliva for various indications, including nonalcoholic steatohepatitis (NASH); and several other product candidates in various stages of clinical and preclinical development. It has a license agreement with Sumitomo Dainippon Pharma Co. Ltd. for the research, development, and commercialization of OCA as a therapeutic for the treatment of PBC and NASH in Japan and China; and Aralez Pharmaceuticals Canada Inc to develop and commercialize bezafibrate in the United States. The company markets its products through an internal commercial organization, a contract sales organization, and third-party distributors. Intercept Pharmaceuticals, Inc. was founded in 2002 and is headquartered in New York, New York.

Technical Indicators

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2020-07-08 )

Largest Industry Peers for Biotechnology

Symbol Name Price(Change) Market Cap Price / Earning Ratio EV/EBITDA
VRTX Vertex Pharmaceuticals Incorpo..

-3.14 (-1.05%)

USD76.11B 50.45 37.87
REGN Regeneron Pharmaceuticals, Inc

-0.54 (-0.08%)

USD65.50B 31.28 21.67
SGEN Seattle Genetics, Inc

-0.61 (-0.35%)

USD30.38B N/A N/A
ALXN Alexion Pharmaceuticals, Inc

-4.46 (-3.97%)

USD23.85B 10.60 9.11
INCY Incyte Corporation

-0.38 (-0.35%)

USD23.62B 47.64 35.20
BMRN BioMarin Pharmaceutical Inc

+0.75 (+0.59%)

USD23.14B 201.24 120.72
MRNA Moderna, Inc

+0.49 (+0.80%)

USD22.86B N/A N/A
GMAB Genmab A/S

+0.86 (+2.50%)

USD22.35B 60.04 6.37
ALNY Alnylam Pharmaceuticals, Inc

+0.42 (+0.26%)

USD18.21B N/A N/A
BNTX BioNTech SE

-1.78 (-2.57%)

USD15.72B -99,999.99 N/A

ETFs Containing ICPT

Symbol Name Weight Mer Price(Change) Market Cap

N/A

Market Performance

  Market Performance vs.
Industry/Classification (Biotechnology)
Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain -64.45% 3% F 3% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -64.45% 3% F 3% F
Trailing 12 Months  
Capital Gain -44.78% 19% F 16% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -44.78% 19% F 16% F
Trailing 5 Years  
Capital Gain -81.89% 28% F 12% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -81.89% 28% F 11% F
Average Annual (5 Year Horizon)  
Capital Gain -8.85% 36% F 17% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -8.85% 35% F 17% F
Risk Return Profile  
Volatility (Standard Deviation) 39.62% 54% F 28% F
Risk Adjusted Return -22.35% 39% F 21% F
Market Capitalization 1.45B 80% B- 75% C
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 97%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Key Financial Ratios

  Ratio vs. Industry/Classification
(Biotechnology)
Ratio vs. Market
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
Market Value  
Price / Earning Ratio N/A N/A N/A N/A N/A
Price/Book Ratio 44.19 4% F 2% F
Price / Cash Flow Ratio -6.13 51% F 76% C
EV/EBITDA N/A N/A N/A N/A N/A
Management Effectiveness  
Return on Equity -295.33% 8% F 4% F
Return on Invested Capital -64.15% 49% F 15% F
Return on Assets -35.43% 37% F 11% F
Debt to Equity Ratio 1,032.04% 2% F 1% F
Technical Ratios  
Short Ratio 7.53 23% F 14% F
Short Percent 27.92% 3% F 8% F
Beta 1.77 40% F 20% F
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 97%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

Fundamental Analysis Breakdown

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
High market capitalization

This is one of the largest entities in its sector and is among the top quartile. Such companies tend to be more stable.

Superior Revenue Growth

This stock has shown top quartile revenue growth in the previous 5 years compared to its sector.

High Gross Profit to Asset Ratio

This stock is in the top quartile compared to its peers on Gross Profit to Asset Ratio. This is a popular measure among value investors for showing superior returns in the long run.

What to not like:
Poor risk adjusted returns

This company is delivering below median risk adjusted returns in its peers. Even if it is outperforming on returns , the returns are unpredictable. Proceed with caution.

Below median dividend returns

The company’s average income yield over the past 5 years has been low compared to its peers. However, it is not a problem if you are not looking for income.

Overpriced compared to book value

The stock is trading high compared to its peers median on a price to book value basis.

Higly leveraged

The company is in the bottom half compared to its sector peers on debt to equity and is highly leveraged. However, do check the news and look at its sector and management statements. Sometimes this is high because the company is trying to grow aggressively.

Negative cashflow

The company had negative total cash flow in the most recent four quarters.